Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.84
-0.4700-3.28%
Post-market: 13.840.00000.00%19:30 EDT
Volume:655.46K
Turnover:9.22M
Market Cap:764.58M
PE:-5.02
High:14.58
Open:14.23
Low:13.80
Close:14.31
52wk High:16.93
52wk Low:6.96
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.49
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.88
PE(LYR):-5.72

Loading ...

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Cantor Fitzgerald Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Aug 14

Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials

TIPRANKS
·
Aug 14

4D Molecular Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 Net Loss Widens

Reuters
·
Aug 14

4D Molecular Therapeutics Q2 EPS $(1.04) Beats $(1.06) Estimate, Sales $3.781M Beat $3.100M Estimate

Benzinga Earnings
·
Aug 14

4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million

Reuters
·
Aug 14

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire
·
Aug 14

4D Molecular Therapeutics Inc Expected to Post a Loss of $1.02 a Share - Earnings Preview

Reuters
·
Aug 07

4D Molecular Therapeutics CEO David Kirn Disposes of 12,415 Shares Worth $124,987

Reuters
·
Aug 05

4D Molecular Therapeutics Inc : B. Riley Initiates Coverage with Buy Rating; Target Price $37

THOMSON REUTERS
·
Jul 31

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

MT Newswires Live
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jul 21

4D Molecular Therapeutics Posts Strong 4D-150 Trial Results

TIPRANKS
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 20

4D Molecular Therapeutics Price Target Maintained with a $36.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 19

4D Molecular Therapeutics - 4d-150 Continues to be Well Tolerated with no New Safety Findings

THOMSON REUTERS
·
Jul 19

4dmt Announces Positive 2-year Data from Prism Phase 2B Clinical Trial in a Broad Wet Amd Population

THOMSON REUTERS
·
Jul 19